¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"glycogen debranching enzyme system"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
¿µ¹® glycogen ÇÑ±Û ±Û¸®ÄÚ°Õ, ´ç¿ø
¼³¸í   
  µ¿¹°¿¡¼­ Åº¼öÈ­¹°ÀÇ ÀúÀåÇüÅ·ΠÁַΠ°£¿¡ ´ëºÎºÐÀÌ ÀúÀåµÇ¾î ÀÖ°í ±ÙÀ°¿¡ Á¶±Ý ÀÖ´Ù. Æ÷µµ´çÀ¸·Î ºÐÇØµÇ¾î ÀÌ¿ëµÈ´Ù.
¿µ¹® serum enzyme ÇÑ±Û Ç÷ûȿ¼Ò
¼³¸í   
  Ç÷û ³»¿¡ Æ÷ÇԵǾî Àִ ¿©·¯ °¡Áö È¿¼Ò¸¦ ÀÏÄ´ ¸»ÀÌ´Ù.
¿µ¹® enzyme ÇÑ±Û È¿¼Ò
¼³¸í   
  »ý¹°Ã¼ ¼¼Æ÷¼Ó¿¡¼­ ÇÕ¼ºµÇ°í, ÁַΠ¼¼Æ÷³»¿¡¼­ ÁøÇàµÇ´Â È­ÇйÝÀÀÀ» Ã˸ÅÇϴ ´Ü¹éÁú·Î ½ÃÇè°ü³»¿¡¼­µµ °°Àº Ã˸ÅÀÛ¿ëÀ» ÇÑ´Ù. ÀÌ È¿¼Ò´Â ÀΰøÀûÀ¸·Î ¸¸µç ¾î¶² Ã˸ÅÁ¦º¸´Ù ±× Æ¯À̼º°ú Ã˸ÅÀÛ¿ëÀ̠Ź¿ùÇѠƯº°ÇÑ »ýüºÐÀÚÀÌ´Ù. ½ÅÁø´ë»ç, Áï ¼¼Æ÷³»¿¡¼­ ÀϾ´Â ¹°ÁúÀÇ È­ÇÐÀû º¯È¯Àº È¿¼ÒÀÇ ÀÛ¿ë¿¡ ÀÇÇØ ¸Å¿ì ºü¸£°í ¿øÇÒÇϰԠÀÌ·ç¾îÁø´Ù. À̰ÍÀº È¿¼ÒÀÇ Ã˸ŠȿÀ²ÀÌ ³ôÀº Á¡°ú È¿¼ÒÀÇ ±âÁú Æ¯À̼º ¶§¹®ÀÌ´Ù. È¿¼Ò¹ÝÀÀÀº »ó¿Â, »ó¾Ð, ÃÖÀû pH µî ÀûÀýÇÑ Á¶°Ç ¾Æ·¡¿¡¼­ ÁøÇàµÈ´Ù. ¶Ç È¿¼ÒÀÇ ÁÖü°¡ ´Ü¹éÁúÀ̱⠶§¹®¿¡ ´Ü¹éÁúÀ» º¯¼º½Ã۴ ¿­, °­»ê, °­¾ËÄ®¸®, À¯±â¿ë¸Å µî¿¡ ÀÇÇØ ±× ÀÛ¿ëÀ» ÀҴ´Ù. È¿¼Ò´Â »ýü¿¡ ³Î¸® ºÐÆ÷Çϸç, º¹ÀâÇÏ°í ´Ù¾çÇÑ ´ë»ç¹ÝÀÀÀ» Ã˸ÅÇϱ⠶§¹®¿¡ Á¾·ùµµ ¸¹´Ù. ¾Õ¼­ ¸»ÇÑ ¹Ù¿Í °°ÀÌ ´ëºÎºÐÀÇ È¿¼Ò´Â ¼¼Æ÷³»¿¡ Á¸ÀçÇÏÁö¸¸, Ç÷¾×°ú ±×¿ÜÀÇ °£Áú¾×¿¡ µé¾î Àֱ⵵ ÇÏ°í ¼ÒÈ­È¿¼Ò·ù󷳠ü¿Ü·Î ºÐºñµÇ´Â °Íµµ ÀÖ´Ù.
¿µ¹® enzyme-linked immunoabsorbent assay ÇÑ±Û È¿¼Ò¸é¿ªÃøÁ¤¹ý
¼³¸í   
  È¿¼Ò°áÇո鿪ÈíÂøÁ¦ °ËÁ¤¹ýÀ¸·Î ¹ø¿ªµÇ°í ÀÖ´Ù. ÀÌ ¹ýÀº Ç׿ø(¶Ç´Â Ç×ü)¿¡ ¾ËÄ®¸® Æ÷½ºÆÄŸ¾ÆÁ¦ ¶Ç´Â Æä¸£¿Á½Ãµð¾ÆÁ¦ µîÀÇ »ê¼Ò¸¦ °áÇÕ½ÃÄÑ µÎ°í ±× »ê¼ÒȰ¼ºÀ» ÁöÇ¥·Î »ï¾Æ Ç׿øÇ×ü¹ÝÀÀÀÇ Á¤µµ¸¦ ¾È ´ÙÀ½ ¿©±â¿¡¼­ Ç׿ø(¶Ç´Â Ç×ü)ÀÇ ¾çÀ» ±¸Çϴ °ÍÀÌ´Ù. ÀÌ ¹ýÀÇ ÀÌÁ¡À¸·Î¼­ °í°¨µµ, Á¶ÀÛÀÇ °£´ÜÇÔ ¹× ¹æ»ç¼±¸é¿ªÃøÁ¤¹ýó·³ ¹æ»ç¼º¹°ÁúÀ» »ç¿ëÇÏÁö ¾Ê¾Æµµ µÈ´Ù´Â Á¡À» µé ¼ö ÀÖ´Ù. È£¸£¸óÀ̳ª ¸é¿ª±Û·ÎºÒ¸°ÀÇ Á¤·®¹ýÀ¸·Î¼­ ÀÀ¿ë µÇ°í ÀÖÀ¸¸ç ÃøÁ¤¿ë Å°Æ®µµ ½ÃÆÇµÇ°í ÀÌÀÖ´Ù.
¿µ¹® hepatic portal system ÇÑ±Û °£¹®¸Æ°è
¼³¸í   
  À§, ÀÛÀºÃ¢ÀÚÀ̳ª Å«Ã¢ÀÚ¿¡¼­ ¿µ¾çºÐÀ» Èí¼öÇϱâ À§ÇÑ ¸ð¼¼Ç÷°üÁ¶Á÷Àº ¸ðµÎ °£À¸·Î ¿¬°áµÈ´Ù. Áï ¼ÒÈ­±â¿¡ Èí¼öÇÑ ¿µ¾çºÐÀÌ °¡µæÇÑ ÇǴ ¸ðµÎ °£À¸·Î ¿¬°áµÇ´Âµ¥ À̰ÍÀ» ¹®¸Æ°è¶ó°í ÇÑ´Ù.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • deposit glycogen
    ÀúÀå±Û¸®ÄÚ°Õ
  • glycogen
    ±Û¸®ÄÚ°Õ, ´ç¿ø
  • glycogen granule
    ±Û¸®ÄÚ°Õ°ú¸³
  • glycogen storage disease
    ±Û¸®ÄÚ°ÕÃàÀûº´, ´ç¿øÃàÀûº´
  • labile glycogen
    ºÒ¾ÈÁ¤±Û¸®ÄÚ°Õ
  • angiotensin converting enzyme
    ¾ØÁö¿ÀÅÙ½ÅÀüȯȿ¼Ò
  • angiotensin converting enzyme inhibitor
    ¾ØÁö¿ÀÅÙ½ÅÀüȯȿ¼Ò¾ïÁ¦Á¦
  • antibody capture enzyme-linked immunosorbent assay
    Ç×üÆ÷ȹȿ¼Ò¸é¿ªÃøÁ¤(¹ý)
  • autolytic enzyme
    ÀÚ°¡¿ëÇØÈ¿¼Ò
  • adaptive enzyme
    ÀûÀÀÈ¿¼Ò
  • allosteric enzyme
    ¾Ë·Î½ºÅ׸®È¿¼Ò
  • blood enzyme level
    Ç÷ÁßÈ¿¼Ò³óµµ
  • brancher enzyme
    °¡ÁöÄ¡±âÈ¿¼Ò, ºÐÁöÈ¿¼Ò
  • branching enzyme
    °¡ÁöÄ¡±âÈ¿¼Ò, ºÐÁöÈ¿¼Ò
  • constitutive enzyme
    ±âº»±¸¼ºÈ¿¼Ò
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • glycogen
    ±Û¸®ÄÚ°Õ, ´ç¿ø
  • enzyme-linked immunosorbent assay
    È¿¼Ò¸é¿ªÃøÁ¤¹ý
  • enzyme
    È¿¼Ò
  • angiotensin converting enzyme
    ¾ÈÁö¿ÀÅÙ½ÅÀüȯȿ¼Ò
  • inhibitory enzyme
    ¾ïÁ¦È¿¼Ò
  • oxidative enzyme
    »êÈ­È¿¼Ò
  • proteolytic enzyme
    ´Ü¹éÁúºÐÇØÈ¿¼Ò
  • rate limiting enzyme
    ¼ÓµµÁ¶ÀýÈ¿¼Ò
  • redox enzyme
    »êȭȯ¿øÈ¿¼Ò
  • regulatory enzyme
    Á¶ÀýÈ¿¼Ò
  • respiratory enzyme
    È£ÈíÈ¿¼Ò
  • restriction enzyme
    Á¦ÇÑÈ¿¼Ò
  • system analysis
    °èÅëºÐ¼®
  • system
    1.°è, °èÅë, ü°è, 2.ÀåÄ¡, 3.Á¦µµ,
  • Bethesta system
    º£Å×½ºÅ¸ºÐ·ù(¹ý)
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • deposit glycogen
    ÀúÀå±Û¸®ÄÚ°Õ
  • glycogen storage disease
    ´ç¿øÃàÀûº´
  • glycogen
    ±Û¸®ÄÚ°Õ, ´ç¿ø
  • glycogen granule
    ±Û¸®ÄÚ°Õ°ú¸³
  • glycogen vacuole
    ´ç¿ø°øÆ÷
  • labile glycogen
    ºÒ¾ÈÁ¤±Û¸®ÄÚ°Õ
  • adaptive enzyme
    ÀûÀÀÈ¿¼Ò
  • allosteric enzyme
    ¾Ë·Î½ºÅ׸®È¿¼Ò
  • angiotensin converting enzyme
    ¾ÈÁö¿ÀÅÙ½ÅÀüȯȿ¼Ò
  • antibody capture enzyme-linked immunosorbent assay
    Ç×üÆ÷ȹȿ¼Ò¸é¿ªÃøÁ¤¹ý
  • autolytic enzyme
    ÀÚ°¡¿ëÇØÈ¿¼Ò
  • double-sandwich enzyme-linked immunosorbent assay
    °ãÈ¿¼Ò¸é¿ªÃøÁ¤¹ý
  • enzyme activity
    È¿¼ÒȰ¼º, È¿¼ÒȰ¼ºµµ
  • enzyme assay
    È¿¼ÒÃøÁ¤
  • enzyme labeled antibody
    È¿¼ÒÇ¥ÁöÇ×ü
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • Glycogen-lactic acid system
    ±Û¸®ÄÚ°Õ-¶ôÆ®»ê°è
  • T-tubular system =>transverse tubular system
    T-°è, °¡·Î¼Ò°ü °èÅë
  • Glycogen
    ±Û¸®ÄÚ°Õ, ´ç¿ø(ÓØê«)
  • Glycogen synthase
    ±Û¸®ÄÚ°ÕÇÕ¼º(ùêà÷)
  • glycogen
    ±Û¸®ÄÚ°Õ, ´ç¿ø
  • glycogen
    ±Û¶óÀÌÄÚÀü, ´ç¿ø.
  • glycogen
    ±Û¸®ÄÚ°Õ, ´ç¿ø.
  • glycogen
    ´ç¿ø, ±Û¸®ÄÚ¿À°Õ
  • glycogen degeneration
    ±Û¸®ÄÚ°Õº¯¼º(¡­Ü¨àõ).
  • glycogen granule
    ±Û¸®ÄÚ°Õ°ú¸³
  • glycogen granule
    ´ç¿ø°ú¸³
  • glycogen phosphorylase
    ±Û¸®ÄÚ°ÕÆ÷½ºÆ÷¸±¶ó¾ÆÁ¦
  • glycogen storage disease
    ±Û¸®ÄÚ°ÕÃàÀû Áúȯ.
  • glycogen storage disease
    ´ç¿ø ÃàÀûÁúȯ(ÓØê«õëîÝòðü´)
  • glycogen storage disease
    ±Û¸®ÄÚ°ÕÃàÀûÁúȯ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • glycine cleavage enzyme system
  • deposit glycogen
    ÀúÀå(îÍíú)±Û¸®ÄÚ°Õ.
  • glycogen
    ±Û¸®ÄÚ°Õ, ´ç¿ø.
  • glycogen
    ´ç¿ø, ±Û¸®ÄÚ¿À°Õ
  • glycogen
    ±Û¶óÀÌÄÚÀü, ´ç¿ø.
  • glycogen
    ±Û¸®ÄÚ°Õ, ´ç¿ø
  • glycogen degeneration
    ±Û¸®ÄÚ°Õº¯¼º(¡­Ü¨àõ).
  • glycogen granule
    ±Û¸®ÄÚ°Õ°ú¸³
  • glycogen granule
    ´ç¿ø°ú¸³
  • glycogen phosphorylase
    ±Û¸®ÄÚ°ÕÆ÷½ºÆ÷¸±¶ó¾ÆÁ¦
  • glycogen storage disease
    ±Û¸®ÄÚ°ÕÃàÀûÁúȯ
  • glycogen storage disease
    ±Û¸®ÄÚ°ÕÃàÀû Áúȯ.
  • glycogen storage disease
    ´ç¿ø ÃàÀûÁúȯ(ÓØê«õëîÝòðü´)
  • glycogen synthase
    ´ç¿ø ÇÕ¼ºÈ¿¼Ò
  • granule, glycogen
    ±Û¸®ÄÚ°Õ°ú¸³
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 11 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • Glycogen granule
    ´ç¿ø°ú¸³
    [¿¾ ¿ë¾î] ´ç¿ø°ú¸³
  • Fornical system
    ³úȰ°èÅë
    [¿¾ ¿ë¾î] ³ú±Ã°è
  • Glial cell of peripheral nervous system
    ¸»ÃʾƱ³¼¼Æ÷
    [¿¾ ¿ë¾î] ¸»Ãʱ³¼¼Æ÷
  • Osteon [Harversian system]
    »À´ÜÀ§
    [¿¾ ¿ë¾î] °ñ¿ø
  • Genital system
    »ý½Ä°èÅë
    [¿¾ ¿ë¾î] »ý½Ä±â°èÅë
  • Cardiac conducting system
    ½ÉÀåÀüµµ°èÅë
    [¿¾ ¿ë¾î] ½ÉÀåÀÚ±ØÀüµµ°è
  • Conduction system of heart
    ½ÉÀåÀüµµ°èÅë
    [¿¾ ¿ë¾î] ½ÉÀåÀüµµ°è
  • CENTRAL NERVOUS SYSTEM
    ÁßÃ߽Űæ°èÅë
    [¿¾ ¿ë¾î] ÁßÃ߽Űæ°è
  • Glial cell of central nervous system
    ÁßÃ߾Ʊ³¼¼Æ÷
    [¿¾ ¿ë¾î] ÁßÃß±³¼¼Æ÷
  • Renal system
    ÄáÆÏ°èÅë
    [¿¾ ¿ë¾î] ½ÅÀå°èÅë
  • Primitive duct system
    ¿ø½Ã°ü°èÅë
    [¿¾ ¿ë¾î] ¿ø½Ã°ü°èÅë
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 2 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • enzyme-linked immunoelectrotransfer blot (EITB)
    È¿¼Ò¸é¿ªÀÌÀû¹ý
  • glycogen vacuoles
    ´ç¿ø°øÆ÷
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • debranching enzyme
    °¡ÁöÁ¦°Å(ð¶ËÛ) È¿¼Ò(ý£áÈ)
  • glycogen
    ±Û¶óÀÌÄÚÀü
  • glycogen granule
    ±Û¶óÀÌÄÚÀü °ú¸³(Ψأ)
  • glycogen phosphorylase
    ±Û¶óÀÌÄÚÀü Æ÷½ºÆ÷¸±·¹À̽º
  • glycogen storage disease
    ±Û¶óÀÌÄÚÀü ÀúÀå Áúȯ(îÍíúòðü´)
  • glycogen synthase
    ±Û¶óÀÌÄÚÀü ½ÅÅ×À̽º
  • enzyme system
    È¿¼Ò (ý£áÈ) ½Ã½ºÅÛ
  • multisubstrate enzyme system
    ´Ù±âÁúÈ¿¼Ò(ÒýѨòõý£áÈ) ½Ã½ºÅÛ
  • ABO blood group (type) system
    ABOÇ÷¾×Çü (úìäûúþ) ½Ã½ºÅÛ
  • absorption optical system
    Èí¼ö(ýåâ¥) ±¤ÇÐ(ÎÃùÊ) ½Ã½ºÅÛ
  • adiabatic system
    ´Ü¿­(Ó¨æð)½Ã½ºÅÛ
  • ATP regeneration system
    ATPÀç»ý(î¢ßæ) ½Ã½ºÅÛ
  • binding protein transport system
    °áÇÕ ´Ü¹éÁú ¼ö¼Û(Ì¿ùêÓ±ÛÜòõâÃáê) ½Ã½ºÅÛ
  • brain barrier system
    ³úÀ庮(Òàî¡Ûú) ½Ã½ºÅÛ
  • cell-free amino acid incorporating system
    ¹«¼¼Æ÷(Ùíá¬øà) ¾Æ¹Ì³ë»ê ÆíÀÔ(øºìý)¾¾½ºÅÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • glycogen
    ±Û¸®ÄÚ°Õ, ´ç¿ø
  • glycogen storage disease
    ±Û¸®ÄÚ°Õ ÃàÀûÁúȯ
  • ELISA [=enzyme-linked immunosorbent assay]
    ELIZA, ¿¤¸®ÀÚ
  • enzyme
    È¿¼Ò
  • enzyme-linked immunosorbent assay [=ELISA]
    ELISA, ¿¤¸®ÀÚ
  • proteolytic enzyme
    ´Ü¹éÁúºÐÇØÈ¿¼Ò
  • array system
    ¹è¿­ÀåÄ¡, ¹è¿­Ã¼°è
  • cardiovascular system
    ½ÉÀåÇ÷°ü°è
  • central nervous system [=CNS]
    ÁßÃ߽Űæ°è(Åë)
  • CNS [=central nervous system]
    ÁßÃ߽Űæ°è(Åë)
  • conventional film screen system
    ±âÁ¸Çʸ§Ã¼Áµ
  • digestive system
    ¼ÒÈ­±â°èÅë
  • display system
    Ç¥½ÃÀåÄ¡
  • DOS [=disk operating system]
    µð½ºÅ©¿î¿µÃ¼Á¦
  • electronically steered system
    ÀüÀÚÁ¶ÇâÀåÄ¡
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
EIA electroimmunoassay; enzyme immunoassay; enzyme-linked immunosorbent assay; equine infectious anemia;...
ISIS image selected in vivo spectroscopy; imaging science and information system; information system-imag...
PACE Pacing and Clinical Electrophysiology; paired basic amino acid cleaving enzyme; personalized aerobic...
GFFS glycogen and fat-free solid
GSD genetically significant dose; Gerstmann-Straussler disease; glutathione synthetase deficiency; glyco...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
GSK-3 beta I)/glycogen synthase kinase-3 beta
Gly Glycogen
GP Glycogen Phosphorylase
GSD Glycogen Storage Disease
GSDII Glycogen Storage Disease type II
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • labile glycogen
    ºÒ¾ÈÁ¤ ±Û¸®ÄÚ°Õ
  • microsomal enzyme system
    ¹Ì¼Òü È¿¼Ò°è
  • neural enzyme system
    ½Å°æ È¿¼Ò°è
  • angiotensin converting enzyme
    ¾ÈÁö¿ÀÅٽŠÀüȯ È¿¼Ò
  • angiotensin-converting enzyme
    ¾ÈÁö¿ÀÅٽŠÀüȯ È¿¼Ò
  • converting enzyme
    Àüȯ È¿¼Ò
  • digestive enzyme
    ¼ÒÈ­ È¿¼Ò
  • enzyme activator
    È¿¼Ò Ȱ¼ºÁ¦
  • enzyme disorder
    È¿¼Ò Àå¾Ö
  • enzyme immunoassay
    È¿¼Ò ¸é¿ª ÃøÁ¤¹ý
    ¼Ò·®ÀÌ¶óµµ ±× Ȱ¼ºÀ» °ËÃâÇÒ ¼ö ÀÖ´Â °í°¨µµÀÇ È¿¼Ò¸¦ Ç¥½ÃÀÚ·Î Çϰí Ç׿ø ȤÀº Ç×ü, ³ª¾Æ°¡¼­´Â ƯÀÌÀûÀ¸·Î ¹ÝÀÀÇÏ´Â ¹°Áú, lectin, C1q µîÀ» È­ÇÐÀûÀ¸·Î °áÇÕ½ÃÄÑ, Ç׿ø ȤÀº Ç×ü µûÀ§¸¦ ÃøÁ¤ÇÏ´Â ¹æ¹ýÀÌ´Ù.
  • enzyme inhibition
    È¿¼Ò ¾ïÁ¦
  • enzyme labeled antibody
    È¿¼Ò Ç¥Áö Ç×ü
  • enzyme marker study
    È¿¼Ò Ç¥Áö ¿¬±¸
  • enzyme precursor
    È¿¼Ò Àü±¸Ã¼
  • enzyme-labelled antibody
    È¿¼Ò Ç¥Áö Ç×ü
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
glycogen debranching enzyme system 1,4-alpha-d-glucan-1,4-alpha-d-glucan 4-alpha-d-glucosyltransferase/dextrin 6 alpha-d-glucanohydrolase. An enzyme system having both 4-alpha-glucanotransferase (ec 2.4.1.25) and amylo-1,6-glucosidase (ec 3.2.1.33) activities. As a transferase it transfers a segment of a 1,4-alpha-d-glucan to a new 4-position in an acceptor, which may be glucose or another 1,4-alpha-d-glucan. As a glucosidase it catalyses the endohydrolysis of 1,6-alpha-d-glucoside linkages at points of branching in chains of 1,4-linked alpha-d-glucose residues. Amylo-1,6-glucosidase activity is deficient in glycogen storage disease type III.
(12 Dec 1998)
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
debranching enzymes Enzyme's that bring about destruction of branches in glycogen; formerly considered to be one enzyme, now known to be a mixture of transferases (4-alpha-d-glucanotransferase) and hydrolases (amylo-1,6-glucosidase).
Synonym: debranching factors.
(05 Mar 2000)
debranching factors Enzyme's that bring about destruction of branches in glycogen; formerly considered to be one enzyme, now known to be a mixture of transferases (4-alpha-d-glucanotransferase) and hydrolases (amylo-1,6-glucosidase).
Synonym: debranching factors.
(05 Mar 2000)
brancher glycogen storage disease Type of glycogen storage disease, due to deficiency of amylo-1,4-1,6-transglucosidase (brancher enzyme).
Synonym: brancher deficiency glycogenosis, debrancher deficiency.
(05 Mar 2000)
glycogen <biochemistry> Branched polymer of D glucose (mostly _(1-4) linked, but some _(1-6) at branch points).
Size range very variable, up to 10exp5 glucose units. Major short term storage polymer of animal cells and is particularly abundant in the liver and to a lesser extent in muscle. In the electron microscope glycogen has a characteristic asterisk or star appearance.
(18 Nov 1997)
glycogen granule Glycogen occurring in cells as beta granule's which average about 300 A
glycogen phosphorylase <enzyme> Enzyme that catalyses the sequential removal of glycosyl residues from glycogen to yield one glucose-1-phosphate per reaction. Its activity is controlled by phosphorylation (by phosphorylase kinase).
(21 Jun 2000)
glycogen storage disease <hepatology> A group of inherited metabolic disorders involving the enzymes responsible for the synthesis and degradation of glycogen. In some patients, prominent liver involvement is presented. In others, more generalised storage of glycogen occurs, sometimes with prominent cardiac involvement.
Synonym: glycogenosis
(12 Sep 2002)
glycogen storage disease type I <disease> An autosomal recessive disease in which gene expression of glucose-6-phosphatase is absent, resulting in hypoglycaemia due to lack of glucose production.
Accumulation of glycogen in liver and kidney leads to organomegaly, particularly massive hepatomegaly. Increased concentrations of lactic acid and hyperlipidemia appear in the plasma. Clinical gout often appears in early childhood.
Inheritance: autosomal recessive.
(12 Dec 1998)
glycogen storage disease type II <disease> Glycogenosis due to alpha-1,4-glucosidase (acid maltase) deficiency. It affects muscle, heart, and other organs.
(12 Dec 1998)
glycogen storage disease type III <disease> An autosomal recessive metabolic disorder due to deficient expression of amylo-1,6-glucosidase (one part of the glycogen debranching enzyme system).
The clinical course of the disease is similar to that of glycogen storage disease type I, but milder. Massive hepatomegaly, which is present in young children, diminishes and occasionally disappears with age. Levels of glycogen with short outer branches are elevated in muscle, liver, and erythrocytes. Six subgroups have been identified, with subgroups type IIIa and type IIIb being the most prevalent.
Inheritance: autosomal recessive
(12 Dec 1998)
glycogen storage disease type IV <disease> An autosomal recessive metabolic disorder due to a deficiency in expression of branching enzyme (alpha-1,4-glucan-6-alpha-glucosyltransferase), resulting in an accumulation of abnormal glycogen with long outer branches. Clinical features are muscle hypotonia and cirrhosis. Death from liver disease usually occurs before age 2.
Inheritance: autosomal recessive
(12 Dec 1998)
glycogen storage disease type V <disease> Glycogenosis due to muscle phosphorylase deficiency. Characterised by painful cramps following sustained exercise.
Inheritance: autosomal recessive
(12 Dec 1998)
glycogen storage disease type VI <disease> A hepatic glycogen storage disease in which there is an apparent deficiency of hepatic phosphorylase activity. However, studies have not been able to distinguish between phosphorylase deficiency and phosphorylase kinase deficiency in patients with hepatic glycogenosis.
(12 Dec 1998)
glycogen storage disease type VII <disease> An autosomal recessive muscle glycogen storage disease in which there is deficient expression of muscle phosphofructokinase activity, resulting in increased concentrations of glucose-6-phosphate and fructose-6-phosphate and low concentrations of fructose-1,6-diphosphate in muscle tissue.
Glycogen storage in muscle is increased, perhaps due to activation of glycogen synthase by accumulated glucose-6-phosphate. It has been proposed that shunting of glucose-6-phosphate and fructose-6-phosphate into the pentose phosphate pathway may result in increased synthesis of purines and pyrimidines, causing hyperuricaemia and gout.
Erythrocytes from patients may show decreased phosphofructokinase activity and 2,3-diphosphoglycerate deficiency. Exercise intolerance is present and severe congenital muscular dystrophy has been reported.
Inheritance: autosomal recessive
(12 Dec 1998)
glycogen storage disease type VIII <disease> An x-linked recessive hepatic glycogen storage disease resulting from lack of expression of phosphorylase-b-kinase activity. Symptoms are relatively mild; hepatomegaly, increased liver glycogen, and decreased leukocyte phosphorylase are present. Liver shrinkage occurs in response to glucagon.
Inheritance: X-linked recessive
(12 Dec 1998)
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 1 ÆäÀÌÁö: 1
  • Glycogen Debranching Enzyme System - »õâ 1,4-alpha-D-Glucan-1,4-alpha-D-glucan 4-alpha-D-glucosyltransferase/dextrin 6 alpha-D-glucanohydrolase. An enzyme system having both 4-alpha-glucanotransferase (EC 2.4.1.25) and amylo-1,6-glucosidase (EC 3.2.1.33) activities. As a transferase it transfers a segment of a 1,4-alpha-D-glucan to a new 4-position in an acceptor, which may be glucose or another 1,4-alpha-D-glucan. As a glucosidase it catalyzes the endohydrolysis of 1,6-alpha-D-glucoside linkages at points of branching in chains of 1,4-linked alpha-D-glucose residues. Amylo-1,6-glucosidase activity is deficient in glycogen storage disease type III.
    Synonyms : Debranching Enzyme, Glycogen, Enzyme, Glycogen Debranching, Transfer Glucosidase
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • glycogen
    ±Û¸®ÄÚ°Õ
  • Temin enzyme
    Å׹Πȿ¼Ò(RNA¿¡¼­ DNA¸¦ ¸¸µå´Â ¿ªÀü»ç È¿¼Ò)
  • enzyme
    È¿¼Ò
  • enzyme detergent
    È¿¼Ò ¼¼Á¦
  • enzyme engineering
    È¿¼Ò °øÇÐ(È¿¼Ò(ÀÛ¿ë)ÀÇ ³ó°ø¾÷¿¡ÀÇ ÀÀ¿ë)
  • respiratory enzyme
    È£ÈíÈ¿¼Ò
  • restriction enzyme
    Á¦ÇÑ È¿¼Ò(µÎÁÙ »ç½½ DNA¸¦ ƯÁ¤ ºÎÀ§¿¡¼­ Àý´ÜÇÏ´Â È¿¼Ò)
  • system
    Á¶Á÷,°èÅë,¹æ½Ä
  • Bertillon system
    º£¸£Æ¼¿ë½Ä ¹üÀνĺ°¹ý(Áö¹®À» Áß½Ã)
  • CAPTAIN System
    ĸƾ½Ã½ºÅÛ(°¡Á¤ÀÇ À¯¼± ÅÚ·¹ºñÀü¿¡ÀÇ Á¤º¸ Á¦°ø ½Ã½ºÃÀ,»óÇ¥¸í)
  • Continental System
    ´ë·úºÀ¼â(1806³â NapoleonÀÇ ¿µ±¹¿¡ ´ëÇÑ)
  • Copernican system
    ÄÚÆä¸£´ÏÄí½º¼³(ü°è);(žçÁ߽ɼ³,Áöµ¿¼³)
  • Dewey classification system
    µµ¼­ÀÇ µàÀÌ 10Áø ºÐ·ù¹ý
  • Dolby system
    µ¹ºñ¹æ½Ä(³ìÀ½ Å×ÀÌÇÁÀÇ ÀâÀ½À» ÁÙÀÌ´Â ¹æ¹ý)
  • Doppler Lidar System
    µµÇ÷¯ È¿°ú¸¦ ÀÌ¿ëÇÑ ±¤ÇÐ½Ä ¼Óµµ°è
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
ÅëÇÕ°Ë»ö ¿Ï·á